Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306103 | 1.00 | ACE (0.34) | ACESMN1; SMN2MAPTPOLBL3MBTL1 | |
| SCHEMBL18305954 | 1.00 | ACE (0.34) | ACESMN1; SMN2MAPTPOLBL3MBTL1 | |
| SCHEMBL22772528 | 0.82 | MAOA (0.40) | — | |
| SCHEMBL22300991 | 0.79 | BRD4 (0.47) | BRD4 | |
| SCHEMBL10284517 | 0.75 | CYP2C9 (0.34) | SMN1; SMN2POLBL3MBTL1CYP2C9GAA | |
| SCHEMBL8294508 | 0.73 | L3MBTL1 (0.49) | ACEPOLBL3MBTL1 | |
| SCHEMBL3271191 | 0.72 | L3MBTL1 (0.45) | POLBL3MBTL1CYP2C9GAA | |
| SCHEMBL16869473 | 0.72 | CYP3A4 (0.38) | ACEMAPTPOLBBRD4GAA | |
| SCHEMBL9057946 | 0.71 | — | — | |
| SCHEMBL925260 | 0.71 | SIRT1 (0.48) | SMN1; SMN2POLBL3MBTL1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107949562-B | Positive allosteric modulators of muscarinic M2 receptors | 拜耳制药股份公司 | 2021-07-23 | — | — | CN | disclosed |
| US-8114867-B2 | Oxazolidinone antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | OXA1L, XDH, CCNY | ACE 3198/4885SMN1; SMN2 2745/4885MAPT 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.